Notably, a study investigating SGLT2 inhibitors in patients with glomerulonephritis observed a significant reduction in proteinuria, but the effect was more pronounced in individuals with higher BMI, suggesting that the antiproteinuric efficacy of SGLT2 inhibitors may be enhanced in overweight and obese patients, likely due to the fluid retention often seen in this population [24]. Here, SLC5A2 is linked to glomerulonephritis.